Anavex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Anavex and other ETFs, options, and stocks.

About AVXL

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. 

CEO
Christopher U. Missling
CEOChristopher U. Missling
Employees
42
Employees42
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2004
Founded2004
Employees
42
Employees42

AVXL Key Statistics

Market cap
314.25M
Market cap314.25M
Price-Earnings ratio
-10.04
Price-Earnings ratio-10.04
Dividend yield
Dividend yield
Average volume
2.57M
Average volume2.57M
High today
$6.00
High today$6.00
Low today
$2.61
Low today$2.61
Open price
$2.94
Open price$2.94
Volume
21.54M
Volume21.54M
52 Week high
$14.44
52 Week high$14.44
52 Week low
$2.61
52 Week low$2.61

Stock Snapshot

Anavex(AVXL) stock is priced at $3.66, giving the company a market capitalization of 314.25M. It carries a P/E multiple of -10.04.

As of 2025-11-14, Anavex(AVXL) stock has fluctuated between $2.61 and $6.00. The current price stands at $3.66, placing the stock +40.2% above today's low and -39.0% off the high.

The Anavex(AVXL)'s current trading volume is 21.54M, compared to an average daily volume of 2.57M.

During the past year, Anavex(AVXL) stock moved between $2.61 at its lowest and $14.44 at its peak.

During the past year, Anavex(AVXL) stock moved between $2.61 at its lowest and $14.44 at its peak.

AVXL News

TipRanks 7h
Why Is Anavex Life Sciences Stock Down Today?

Anavex Life Sciences (AVXL) stock plummeted on Friday after the clinical-stage biopharmaceutical company announced a regulatory update concerning oral blarcames...

TipRanks 8h
Anavex to request re-examination of CHMP opinion on MAAA for blarcamesine

Anavex (AVXL) Life Sciences provides a regulatory update on blarcamesine for early Alzheimer’s disease. The Company was informed by the Committee for Medicinal...

People also own

Based on the portfolios of people who own AVXL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.